HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $5 to $8.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $5 to $8.